EU mobilizes 10 million euros for research on the new coronavirus outbreak

31 January 2020
europe_flag_eu_big

The European Commission announced yesterday that it will grant 10 million euros ($11 million) from its research and innovation program, Horizon 2020, to support research into the new coronavirus disease.

It has launched an  emergency request for expressions of interest for research projects that will advance our understanding of the novel coronavirus epidemic and contribute to more efficient clinical management of patients infected with the virus, as well as improve public health preparedness and response.

Mariya Gabriel, Commissioner for Innovation, Research, Culture, Education and Youth, said: "We are working to mitigate the consequences of a potential larger spread of the coronavirus outbreak in the EU. Thanks to emergency research funding from Horizon 2020, we will know more about the disease. I am proud that following the progress made during the last years, our supercomputer centres stand ready to help researchers in their work to develop new treatment and vaccines. We will be able to protect the public better, and to deal more effectively with the current and any future outbreaks.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight